Validation data for RBD-Lucia

https://www.invivogen.com/wuhan-rbd-lucia

For research use only

Version 21I17-NJ

RBD-Lucia is a soluble fusion protein composed of the Receptor Binding Domain (RBD) from the original SARS-CoV-2 Spike protein fused to a C-terminal Lucia luciferase reporter. This fusion protein has been specifically designed to assess the binding affinity of anti-Spike antibodies using either ELISA (Fig 1), or the solution phase assay LIPS (luciferase immunoprecipitation systems) (Fig 2).

RBD-Lucia for a Luciferase-based ELISA

Unlike a conventional ELISA, the plate was coated overnight with an Anti-murine IgG F(ab')2 fragment as the 'capture antibody'. InvivoGen's collection of clinically relevant anti-Spike monoclonal antibodies (mAb) were added and the binding affinity of these mAbs to RBD-Lucia was assessed using the Lucia luciferase activity.



Figure 1: Luciferase-based ELISA using RBD-Lucia. Anti-murine IgG F(ab')2 fragment (2 μ g/ml) was coated on an ELISA plate overnight. Anti-CoV2RBD-cas-mIgG2a, Anti-CoV2RBD-imd-mIgG2a, Anti-CoV2RBD-bam-mIgG2a, Anti-CoV2RBD-ete-mIgG2a, or the negative control Anti- β Gal-mIgG2a, along with RBD-Lucia (1 μ g/ml) were added and incubated for 2 hours at room temperature. After washing (3x times), binding affinity was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-LucTM. Data are shown as a fold change over no antibody.

RBD-Lucia for LIPS

RBD-Lucia can be used to detect anti-spike polyclonal antibodies in the sera of recovered COVID-19 patients and/or a vaccinee. Antibody-protein complexes are purified and quantification is easily determined by assessing the Lucia luciferase activity.



Figure 2: Detection of Spike antibodies in vaccinee sera by LIPS. RBD-Lucia (10 µg/ml) was mixed with either diluted serum from individuals vaccinated against SARS-CoV-2 (Sample 1-3) or Anti-CoV2RBD-imd-mlgG2a (mAb) diluted in 'negative' serum. Protein A beads were added to the mixture and incubated at room temperature for 2 hours with gnetly shaking. After extensive washing (6x times), detection of anti-Spike antibodies was assessed by measuring the activity of Lucia luciferase in the supernatant using QUANTI-Luc[™]. Data are shown as a fold change over 'negative' serum (or no antibody).

TECHNICAL SUPPORT InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Asia: +852 3-622-34-80 E-mail: info@invivogen.com

